Clinical Trials Browser

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04620603 2026-05-05

Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer

Phase 1 Active not recruiting

5 enrolled

DermatologicGenitourinary

Melanoma, Cutaneous Malignant, Carcinoma, Renal Cell

NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Phase 1 Active not recruiting

12 enrolled 13 charts

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT02732275 2026-04-28

DS-3201b in Participants With Lymphomas

Phase 1 Active not recruiting

100 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04483778 2026-04-28

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Phase 1 Active not recruiting

68 enrolled

CNSDermatologicGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Carcinoma, Melanoma, Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Hepatoblastoma, Sarcoma, Clear Cell, Neurofibrosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT04913285 2026-04-27

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Phase 1 Active not recruiting

400 enrolled

DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Thyroid Diseases

NCT06153238 2026-04-23

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Phase 1 Active not recruiting

322 enrolled

Dermatologic

Melanoma

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT01590069 2026-04-21

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Phase 1 Active not recruiting

70 enrolled

DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Sarcoma, Osteosarcoma

NCT05571839 2026-04-20

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Phase 1 Active not recruiting

41 enrolled

DermatologicGastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05470283 2026-04-16

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Phase 1 Active not recruiting

21 enrolled

Dermatologic

Melanoma, Neoplasms

NCT01955460 2026-04-15

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

Phase 1 Active not recruiting

34 enrolled

Dermatologic

Melanoma

NCT01303341 2026-04-13

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Phase 1 Active not recruiting

35 enrolled

Dermatologic

Melanoma

NCT01364051 2026-04-13

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Phase 1 Active not recruiting

19 enrolled

Dermatologic

Melanoma

NCT01366144 2026-04-13

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Phase 1 Active not recruiting

94 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Unknown Primary, Ovarian Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Liver Failure, Renal Insufficiency

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Phase 1 Active not recruiting

62 enrolled

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT02520791 2026-04-13

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Phase 1 Active not recruiting

21 enrolled

DermatologicLymphoid

Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT05858736 2026-04-09

PRESERVE-009

Phase 1 Active not recruiting

18 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04044859 2026-04-07

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Phase 1 Active not recruiting

120 enrolled

DermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06566092 2026-04-06

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

Phase 1 Active not recruiting

40 enrolled

DermatologicSarcoma

Melanoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT05496686 2026-04-03

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma

Phase 1 Active not recruiting

16 enrolled

Dermatologic

Uveal Melanoma, Neoplasm Metastasis, Uveal Neoplasms

NCT05614102 2026-03-31

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

284 enrolled

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1 Active not recruiting

210 enrolled

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04835805 2026-03-30

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Phase 1 Active not recruiting

65 enrolled

Dermatologic

Melanoma

NCT04930783 2026-03-25

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Melanoma

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Skin Neoplasms

NCT04514484 2026-03-23

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Phase 1 Active not recruiting

8 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Kaposi, HIV Infections, Carcinoma, Medullary, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Phase 1 Active not recruiting

36 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT04020809 2026-03-09

Neoadjuvant Atezolizumab in Cutaneous Melanoma

Phase 1 Active not recruiting

20 enrolled

Dermatologic

Melanoma

NCT06961786 2026-03-05

TUNINTIL-2

Phase 1 Active not recruiting

9 enrolled

Dermatologic

Melanoma

NCT02721459 2026-03-02

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Phase 1 Active not recruiting

26 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

Phase 1 Active not recruiting

36 enrolled

BreastDermatologicGastrointestinalThoracic

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT05869539 2026-02-27

BaseTIL-03M

Phase 1 Active not recruiting

10 enrolled

Dermatologic

Advanced Melanoma

NCT05907304 2026-02-27

SEACRAFT-1

Phase 1 Active not recruiting

86 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Phase 1 Active not recruiting

2 enrolled

Dermatologic

Melanoma

NCT06014086 2026-02-11

Intratumoral PH-762 for Cutaneous Carcinoma

Phase 1 Active not recruiting

30 enrolled

Dermatologic

Melanoma

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

150 enrolled

DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT04459273 2026-02-05

FAPI PET RDRC

Phase 1 Active not recruiting

26 enrolled

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckNETOther hematologic neoplasm

Adrenal Gland Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Unknown Primary, Skin Neoplasms, Testicular Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Hematologic Neoplasms

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Phase 1 Active not recruiting

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT03891953 2026-01-21